253584-86-0Relevant academic research and scientific papers
PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES
-
, (2012/11/06)
The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
Easier preparation of 2,6-Di-tert-butylphenyl derivatives 1
Knorr, Rudolf,Rossmann, Eva Christine,Knittl, Monika
experimental part, p. 2124 - 2128 (2010/09/04)
Despite steric shielding by the 2,6-di-tert-butylphenyl group (super-2,6-xylyl=xyl*), inexpensive sodium phenolate (xyl*-ONa) reacts with dimethyl sulfate to produce only xyl*-OCH3 (94%) with complete suppression of the alternative 4-methylation. Reductive cleavage of xyl*-OCH3 by elemental lithium with the help of an electron carrier generates xyl*-Li, which in turn yields xyl*-CO2H (63%). The corresponding 4-methyl-derivatives of these compounds were obtained analogously. The acid chloride xyl*-COCl (77% yield) acylates HalMgCH 2R to give only xyl*-COCH3 (86%) or xyl*-COEt (97%). These two ketones react with n-butyllithium (no carbonyl addition) and Cl-PO(OEt)2 to furnish only the enol phosphates xyl*-C(=CH 2)OPO(OEt)2 (84%) or xyl*-C(=CHCH 3)OPO(OEt)2 (up to 70%), respectively. Only 1,2-elimination occurs when the latter two products are treated with tert-butyllithium, affording xyl*-CCH (68%) or xyl*-CCMe (88%), respectively. Georg Thieme Verlag Stuttgart - New York.
